{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:32:14Z","timestamp":1790875934660,"version":"4.1.0"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Researchers Supporting Project at King Saud University, Riyadh, Saudi Arabia","award":["RSPD2024R885"],"award-info":[{"award-number":["RSPD2024R885"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>The epidermal growth factor receptor (EGFR), a crucial component of cellular signaling pathways, is frequently dysregulated in a range of cancers. EGFR targeting has become a viable approach in the development of anti-cancer medications. This study employs an integrated approach to drug discovery, combining multiple computational methodologies to identify potential EGFR inhibitors. The co-crystal ligand for the EGFR protein (R85) (PDB ID: 7AEI) was employed as a model for developing pharmacophore hypotheses. Nine databases underwent a ligand-based virtual screening, and 1271 hits meeting the screening criteria were chosen. EGFR protein crystal structure was obtained from the PDB database (PDB ID: 7AEI) and prepared. The hit compounds identified during virtual screening were docked to the prepared EGFR receptor to predict binding affinities by using the glide tool\u2019s standard precision mode. The top ten compounds were chosen, and their affinities of binding ranged from -7.691 to -7.338 kcal\/mol. The ADMET properties of the selected compounds were predicted, and three compounds MCULE-6473175764, CSC048452634, and CSC070083626 showed better QPPCaco values compared to other identified compounds, so these were selected for further stability analysis. To confirm the stability of the protein-ligand complexes, a 200 ns molecular dynamics (MD) simulation was run using the binding sites of the top three compounds against the EGFR receptor. These results suggest that the selected compounds may be lead compounds in suppressing the biological activity of EGFR, additional experimental investigation is required.<\/jats:p>","DOI":"10.1371\/journal.pone.0311527","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T18:33:27Z","timestamp":1733769207000},"page":"e0311527","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":21,"title":["Integration of pharmacophore-based virtual screening, molecular docking, ADMET analysis, and MD simulation for targeting EGFR: A comprehensive drug discovery study using commercial databases"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2565-6573","authenticated-orcid":true,"given":"Abdullah R.","family":"Alanzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7818-3319","authenticated-orcid":true,"given":"Ashaimaa Y.","family":"Moussa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed S.","family":"Alsalhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tayyab","family":"Nawaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ijaz","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,12,9]]},"reference":[{"issue":"1","key":"pone.0311527.ref001","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1517\/14728222.2011.648617","article-title":"Targeting the EGFR signaling pathway in cancer therapy","volume":"16","author":"P. Seshacharyulu","year":"2012","journal-title":"Expert opinion on therapeutic targets"},{"issue":"4","key":"pone.0311527.ref002","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1677\/erc.1.00600","article-title":"Epidermal growth factor receptor inhibition strategies in oncology","volume":"11","author":"P. Harari","year":"2004","journal-title":"Endocrine-related cancer"},{"issue":"1","key":"pone.0311527.ref003","first-page":"6","article-title":"In silico Screening of Violacein as an epidermal growth factor receptor inhibitor","volume":"11","author":"S.S. Bhat","year":"2022","journal-title":"International Journal of Health and Allied Sciences"},{"issue":"34","key":"pone.0311527.ref004","doi-asserted-by":"crossref","first-page":"8690","DOI":"10.1016\/j.biomaterials.2013.07.100","article-title":"Epidermal growth factor receptor targeting in cancer: a review of trends and strategies","volume":"34","author":"C. Yewale","year":"2013","journal-title":"Biomaterials"},{"issue":"5","key":"pone.0311527.ref005","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jtho.2020.12.002","article-title":"Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations","volume":"16","author":"A. Passaro","year":"2021","journal-title":"Journal of Thoracic Oncology"},{"issue":"3","key":"pone.0311527.ref006","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1470-2045(19)30785-5","article-title":"Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study","volume":"21","author":"L.V. Sequist","year":"2020","journal-title":"The Lancet Oncology"},{"issue":"1","key":"pone.0311527.ref007","first-page":"1","article-title":"Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated","volume":"9","author":"S.-Y. Park","year":"2010","journal-title":"Molecular cancer"},{"issue":"6","key":"pone.0311527.ref008","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/ijc.1557","article-title":"ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR\u2010positive cancer cell lines with or without erbB2 overexpression.","volume":"94","author":"N.G. Anderson","year":"2001","journal-title":"International journal of cancer"},{"key":"pone.0311527.ref009","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s10549-012-2003-y","article-title":"A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.","volume":"133","author":"N.U. Lin","year":"2012","journal-title":"Breast cancer research and treatment"},{"issue":"5","key":"pone.0311527.ref010","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.21037\/jtd.2019.08.30","article-title":"Mechanisms of resistance to osimertinib","volume":"12","author":"C. Lazzari","year":"2020","journal-title":"Journal of Thoracic Disease"},{"issue":"7","key":"pone.0311527.ref011","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum\u2013pemetrexed in EGFR T790M\u2013positive lung cancer","volume":"376","author":"T.S. Mok","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"pone.0311527.ref012","doi-asserted-by":"crossref","first-page":"111664","DOI":"10.1016\/j.ejmech.2019.111664","article-title":"Natural products as important tyrosine kinase inhibitors","volume":"182","author":"B. Yin","year":"2019","journal-title":"European journal of medicinal chemistry"},{"key":"pone.0311527.ref013","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.2147\/DDDT.S310820","article-title":"Novel phenolic compounds as potential dual EGFR and COX-2 inhibitors: Design, semisynthesis, in vitro biological evaluation and in silico Insights","author":"M.A. Abdelgawad","year":"2021","journal-title":"Drug design, development and therapy"},{"key":"pone.0311527.ref014","doi-asserted-by":"crossref","first-page":"102997","DOI":"10.1016\/j.bioorg.2019.102997","article-title":"EGFR inhibitors and apoptotic inducers: Design, synthesis, anticancer activity and docking studies of novel xanthine derivatives carrying chalcone moiety as hybrid molecules","volume":"89","author":"H.A. Abou-Zied","year":"2019","journal-title":"Bioorganic chemistry"},{"issue":"6","key":"pone.0311527.ref015","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/cmdc.201700743","article-title":"In silico studies designed to select sesquiterpene lactones with potential antichagasic activity from an in\u2010house asteraceae database","volume":"13","author":"C.H. Acevedo","year":"2018","journal-title":"ChemMedChem"},{"issue":"9","key":"pone.0311527.ref016","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrclinonc.2010.97","article-title":"Understanding resistance to EGFR inhibitors\u2014impact on future treatment strategies","volume":"7","author":"D.L. Wheeler","year":"2010","journal-title":"Nature reviews Clinical oncology"},{"issue":"20","key":"pone.0311527.ref017","first-page":"1755","article-title":"Advancements in docking and molecular dynamics simulations towards ligand-receptor interactions and structure-function relationships.","volume":"18","author":"A.A. Naqvi","year":"2018"},{"issue":"W1","key":"pone.0311527.ref018","first-page":"W442","article-title":"Pharmit: interactive exploration of chemical space","volume":"44","author":"J. Sunseri","year":"2016"},{"issue":"6","key":"pone.0311527.ref019","first-page":"2663","article-title":"Multi-conformational frame from molecular dynamics as a structure-based pharmacophore model for mapping, screening and identifying ligands against PPAR-\u03b3: a new protocol to develop promising candidates.","volume":"40","author":"P. Prabitha","year":"2022"},{"key":"pone.0311527.ref020","author":"G.O. Oduselu","year":"2021","journal-title":"Structure-Based drug design in discovering target specific drugs against plasmodium falciparum adenylosuccinate lyase"},{"key":"pone.0311527.ref021","author":"LigPrep","year":"2018"},{"issue":"8","key":"pone.0311527.ref022","first-page":"2553","article-title":"Improving the prediction of absolute solvation free energies using the next generation OPLS force field.","volume":"8","author":"D. Shivakumar","year":"2012"},{"key":"pone.0311527.ref023","first-page":"2017","article-title":"Schr\u00f6dinger, LLC; New York, NY: 2017.","volume":"2","author":"L.J.S.S. Schr\u00f6dinger","year":"2017"},{"issue":"3","key":"pone.0311527.ref024","first-page":"235","article-title":"Effects of histidine protonation and rotameric states on virtual screening of M","volume":"27","author":"M.O. Kim","year":"2013","journal-title":"tuberculosis RmlC."},{"issue":"7","key":"pone.0311527.ref025","first-page":"1739","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1.","volume":"47","author":"R.A. Friesner","year":"2004","journal-title":"Method and assessment of docking accuracy."},{"issue":"1","key":"pone.0311527.ref026","article-title":"Computational studies on imidazo [1, 2-a] pyridine-3-carboxamide analogues as antimycobacterial agents: Common pharmacophore generation, atom-based 3D-QSARmolecular dynamics simulation, QikProp, molecular docking and prime MMGBSA approaches","volume":"5","author":"S.N. Mali","year":"2018"},{"key":"pone.0311527.ref027","article-title":"Scalable algorithms for molecular dynamics simulations on commodity clusters. in Proceedings of the 2006","author":"K.J. Bowers","year":"2006","journal-title":"ACM\/IEEE Conference on Supercomputing"},{"issue":"20","key":"pone.0311527.ref028","first-page":"10096","article-title":"A modified TIP3P water potential for simulation with Ewald summation","volume":"121","author":"D.J. Price","year":"2004"},{"issue":"15","key":"pone.0311527.ref029","first-page":"3993","article-title":"In-Silico molecular docking and simulation studies on novel chalcone and flavone hybrid derivatives with 1, 2, 3-triazole linkage as vital inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase.","volume":"36","author":"M. Thillainayagam","year":"2018"},{"issue":"4","key":"pone.0311527.ref030","first-page":"1518","article-title":"How molecular size impacts RMSD applications in molecular dynamics simulations.","volume":"13","author":"K. Sargsyan","year":"2017"},{"issue":"3","key":"pone.0311527.ref031","first-page":"e0119264","article-title":"Automatic identification of mobile and rigid substructures in molecular dynamics simulations and fractional structural fluctuation analysis.","volume":"10","author":"L.J.P.o. Mart\u00ednez","year":"2015"},{"issue":"13","key":"pone.0311527.ref032","first-page":"2800","article-title":"Molecular modeling study of checkpoint kinase 1 inhibitors by multiple docking strategies and prime\/MM\u2013GBSA calculation.","volume":"32","author":"J. Du","year":"2011"},{"issue":"6","key":"pone.0311527.ref033","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1159\/000279388","article-title":"EGFR signaling and drug discovery","volume":"77","author":"G. Lurje","year":"2010","journal-title":"Oncology"},{"issue":"3","key":"pone.0311527.ref034","doi-asserted-by":"crossref","first-page":"749","DOI":"10.18596\/jotcsa.927426","article-title":"Pharmacophore modeling in drug discovery: methodology and current status","volume":"8","author":"M.T. Muhammed","year":"2021","journal-title":"Journal of the Turkish Chemical Society Section A: Chemistry"},{"issue":"22","key":"pone.0311527.ref035","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.4155\/fmc-2018-0076","article-title":"A review of ligand-based virtual screening web tools and screening algorithms in large molecular databases in the age of big data","volume":"10","author":"A.-J. Banegas-Luna","year":"2018","journal-title":"Future medicinal chemistry"},{"issue":"4","key":"pone.0311527.ref036","doi-asserted-by":"crossref","first-page":"270","DOI":"10.2174\/1574893615666191219094216","article-title":"Relevance of molecular docking studies in drug designing","volume":"15","author":"R. Jakhar","year":"2020","journal-title":"Current Bioinformatics"},{"issue":"7","key":"pone.0311527.ref037","first-page":"1756","article-title":"Allosterically targeting EGFR drug-resistance gatekeeper mutations.","volume":"9","author":"N. Spellmon","year":"2017"},{"issue":"1","key":"pone.0311527.ref038","first-page":"2530","article-title":"Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors.","volume":"13","author":"T.S. Beyett","year":"2022"},{"issue":"3","key":"pone.0311527.ref039","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3390\/cryst10030180","article-title":"Not only hydrogen bonds: Other noncovalent interactions.","volume":"10","author":"I. Alkorta","year":"2020","journal-title":"Crystals"},{"key":"pone.0311527.ref040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12039-020-01794-1","article-title":"C-halogen\u2026 pi interactions in nucleic acids: A database study","volume":"132","author":"D. Mitra","year":"2020","journal-title":"Journal of Chemical Sciences"},{"issue":"1","key":"pone.0311527.ref041","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.drudis.2019.10.014","article-title":"A drug-likeness toolbox facilitates ADMET study in drug discovery","volume":"25","author":"C.-Y. Jia","year":"2020","journal-title":"Drug discovery today"},{"issue":"2","key":"pone.0311527.ref042","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3390\/molecules28020776","article-title":"Evaluation of free online ADMET tools for academic or small biotech environments.","volume":"28","author":"J. Dulsat","year":"2023","journal-title":"Molecules"},{"issue":"1","key":"pone.0311527.ref043","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3390\/pr9010071","article-title":"Molecular dynamics simulations in drug discovery and pharmaceutical development","volume":"9","author":"O.M. Salo-Ahen","year":"2020","journal-title":"Processes"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0311527","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T18:33:40Z","timestamp":1733769220000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0311527"}},"subtitle":[],"editor":[{"given":"Ahmed A.","family":"Al-Karmalawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,12,9]]},"references-count":43,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0311527","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,9]]}}}